Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

3 years ago

ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of MedicalSALT LAKE CITY,…

Cingulate, Indegene to Participate in Benzinga All Live Access Event

3 years ago

KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision…

Cronos Group Inc. to Speak at the Canaccord Genuity 7th Annual Global Cannabis Conference

3 years ago

TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative…

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

3 years ago

IMCA medical center's ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada,…

UPDATE — Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

3 years ago

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash…

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

3 years ago

Table 1 FDA Required Primary Efficacy Endpoint Figure 2 Study BDX-22-006 Primary Endpoint Figure 3 Study BDX-22-006Announced Positive Top-Line Final…

Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

3 years ago

MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company…

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

3 years ago

In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection,…

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

3 years ago

Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from…

Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference

3 years ago

WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of…